Although such an effect was seen in up to 5–8% of target cells, the tumor-penetrating ability can be increased by retargeting AltMV SPV to an alternative receptor such as neuropeptide Y1 [39], IGF-1R [40], or unknown surface proteins detected in our earlier investigation [23]. The gene discussed is IGF1R; the disease is neoplasm.